Flotation

Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.

The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.

The precision cancer therapy developer, which counts Sanofi as a significant shareholder, floated at the top of an upsized range and saw its price continue to rise post-IPO.

The genomic drug developer, which counts GV as an investor, has completed its initial public offering, boosting its size from $180m to $207m.

Drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

The GV and Wuxi AppTec-backed drug development software producer floated above its range and saw its shares rise 68% on their first day of trading.

Alphabet, Editas and Bio Palette-backed genomic medicine developer Beam will raise $180m in an upsized initial public offering three years after being spun out of Harvard University.

The Target-backed mattress and bedding brand is floating at the bottom of its range, at a valuation of less than half that of its last funding round.